docetaxel anhydrous has been researched along with su 11248 in 44 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (su 11248) | Trials (su 11248) | Recent Studies (post-2010) (su 11248) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 4,338 | 560 | 3,200 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (15.91) | 29.6817 |
| 2010's | 35 (79.55) | 24.3611 |
| 2020's | 2 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bai, R; Bastian, A; Choudhary, S; Gangjee, A; Hamel, E; Ihnat, MA; Pavana, RK | 1 |
| von Mehren, M | 1 |
| Saito, Y; Suzuki, Y; Tokuda, Y | 1 |
| Etienne-Grimaldi, MC; Ferrero, JM; Fischel, JL; Formento, P; Guérin, O; Hofman, P; Lo Nigro, C; Merlano, M; Milano, G | 1 |
| Cumashi, A; Iacobelli, S; Lattanzio, R; Natoli, C; Piantelli, M; Rossi, C; Tinari, N | 1 |
| Dror Michaelson, M; Gurski, C; Kantoff, PW; Kaufman, DS; Michaelson, SZ; Oh, WK; Olivier, K; Regan, MM; Smith, MR; Spicer, B | 1 |
| Asmar, L; Bernold, D; Berry, WR; Boehm, KA; Fleming, MT; Galsky, MD; Hutson, TE; Periman, PO; Sonpavde, G; Weckstein, D; Zhan, F | 1 |
| Cardoso, F; Senkus-Konefka, E | 1 |
| Bergh, J; Castany, R; Liljegren, A | 1 |
| Chao, R; Harper, K; Huang, X; Ilagan, J; Liu, G; Robert, F; Sandler, A; Schiller, JH; Traynor, AM; Tye, L; Verkh, L | 1 |
| Chan, AT; Cheng, SH; Cheung, CS; Ho, K; Hui, EP; Lau, CP; Lui, VW; Ma, BB; Ng, MH; Wong, CS | 1 |
| Alberola, V; Casinello, J; Gasent, JM; Grande, E; Laforga, JB; Provencia, M | 1 |
| Angulo, JC | 1 |
| Jiang, Z; Wang, D; Zhang, L | 1 |
| Pan, F; Pan, Y; Tian, J; Zhang, X; Zhang, Y | 1 |
| Chen, I; Chow Maneval, E; George, DJ; Harmon, CS; Hutson, TE; Kozloff, M; Liu, G; Logothetis, CJ; Mathew, P; Shore, ND; Wang, SL; Wilding, G; Zurita, AJ | 1 |
| Cortes, J; Roché, H | 1 |
| Bergh, J; Bischoff, J; Bondarenko, IM; Chan, A; Cortes, J; Delaloge, S; Giorgetti, C; Greil, R; Huang, X; Kern, KA; Lichinitser, MR; Liljegren, A; Lortholary, A; Makhson, AN; Voytko, NL | 1 |
| Awada, A; Bergh, J; Cardoso, F; Gianni, L; Giorgetti, C; Huang, X; Kern, KA; Liljegren, A; Mariani, G; Verkh, L; Viganò, L | 1 |
| Kang, WK; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Yi, JH; Yim, DS | 1 |
| Byun, SS; Hong, SK; Jeong, CW; Jeong, SJ; Kwak, C; Lee, SE; Yoon, CY | 1 |
| Aldrighetti, D; Amadori, D; Bouko, Y; Canon, JL; Cardoso, F; Dirix, L; Giorgetti, C; Kern, KA; Machiels, JP; Usari, T; Verkh, L | 1 |
| Ahmadzadeh, A; Babaei, M; Elahi, F; Hassanpour, K; Yadollahzadeh, M | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Armstrong, AJ; Chen, I; Chow-Maneval, E; Galsky, MD; Lechuga, M; Leopold, L; Michaelson, MD; Mooney, DJ; Paolini, J; Pond, GR; Smith, MR; Sonpavde, G; Wang, SL; Wood, BA | 1 |
| Bahl, A; Castellano, D; Chen, I; Chow Maneval, E; Daugaard, G; Gschwend, J; Houede, N; Jones, R; Laestadius, F; Lechuga, MJ; Maurina, T; Michaelson, MD; Ostler, P; Ou, YC; Oudard, S; Paolini, J; Saad, F; Sengeløv, L; Stenzl, A; Ullèn, A; Wang, SL | 1 |
| Yaqub, F | 1 |
| Bernhardt, A; Fallon, J; Greiner, JW; Guzman, W; Kradjian, G; Lan, Y; Neuteboom, B; Sabzevari, H; Schlom, J; Tighe, R | 1 |
| Armstrong, AJ; Chen, I; Chow-Maneval, E; Clarke, SJ; Lechuga, M; Michaelson, MD; Paolini, J; Pond, GR; Smith, MR; Sonpavde, G; Templeton, AJ; Vardy, JL; Wang, SL | 1 |
| Byun, SS; Cheon, J; Hong, SK; Jeong, SJ; Lee, SE; Moon, du G; Oh, MM; Park, HS; Yoon, CY | 1 |
| Bergh, J; Foukakis, T; Giorgetti, C; Hedayati, E; Jacobsson, H; Lindström, LS; Lövrot, J; Sandqvist, P; Xie, H | 1 |
| Chang, CC; Chen, RJ; Chiou, HY; Hsieh, CC; Hsieh, CI; Lien, YC; Tai, CJ; Tzao, C; Wang, CK; Wu, CH; Wu, HC | 1 |
| Anand, M; Armstrong, AJ; Bratt, L; Carducci, MA; Creel, P; Davis, K; George, DJ; Halabi, S; Healy, P; Hobbs, C; Kim, S; Koontz, BF; Lee, WR; Moul, JW; Mundy, K; Nguyen, M; Reimer, B; Stein, M; Tran, PT; Wood, S | 1 |
| Bergh, J; Betsholtz, C; Foukakis, T; Genové, G; He, L; Landberg, G; Lindström, LS; Östman, A; Tobin, NP; Wennmalm, K | 1 |
| Apolo, AB; De Santis, M; Galsky, MD; Leibovich, BC; Milowsky, MI; Pham, MN; Pisters, LL; Siefker-Radtke, AO; Sonpavde, G; Steinberg, GD; Sternberg, CN; Tagawa, ST; Weizer, AZ; Woods, ME | 1 |
| Cheng, T; Chi, KN; Eigl, BJ; Eliasziw, M; North, S; Parimi, S; Ruether, D; Trudeau, M; Winquist, E | 1 |
| Chen, S; Wang, W; Zhao, L; Zhou, J | 1 |
| Inatsu, H; Kitamura, K; Nakashima, K | 1 |
| Carillio, G; Costanzo, R; Daniele, G; Manzo, A; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Filip-Psurska, B; Kutner, A; Maj, E; Milczarek, M; Psurski, M; Wietrzyk, J | 1 |
| Ang, YLE; Chong, WQ; Goh, BC; Ho, GF; Lee, SC; Lim, JSJ; Ow, SGW; Soe, PP; Soo, RA; Sundar, R; Tai, BC; Tan, SH; Wang, L; Yong, WP | 1 |
| Becerra, CHR; Boyd, TE; Casero, RA; Conkling, PR; Fitzgerald, M; Garbo, LE; Jotte, RM; Marton, LJ; Murray Stewart, T; Richards, DA; Smith, DA; Stephenson, JJ; Vogelzang, NJ; Von Hoff, D; Wu, HH | 1 |
6 review(s) available for docetaxel anhydrous and su 11248
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
New therapeutic strategies for soft tissue sarcomas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dioxoles; Docetaxel; Epothilones; Guanidines; Humans; Indoles; Isoquinolines; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Pyrroles; Sarcoma; Sirolimus; Sunitinib; Taxoids; Tetrahydroisoquinolines; TOR Serine-Threonine Kinases; Trabectedin | 2003 |
[Molecular-targeted agents in breast cancer].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Drug Delivery Systems; Female; Humans; Indoles; Lapatinib; Middle Aged; Paclitaxel; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sunitinib; Taxoids; Trastuzumab | 2006 |
Docetaxel combined with targeted therapies in metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Indoles; Lapatinib; Pyrroles; Quinazolines; Sunitinib; Taxoids; Trastuzumab | 2012 |
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Taxoids; Ureteral Neoplasms | 2017 |
Angiogenesis Inhibitors in NSCLC.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyrroles; Quinazolines; Ramucirumab; Sorafenib; Sunitinib; Taxoids | 2017 |
19 trial(s) available for docetaxel anhydrous and su 11248
| Article | Year |
|---|---|
Phase II study of sunitinib in men with advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Angiogenic Proteins; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplasm; Humans; Indoles; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Radiography; Sunitinib; Taxoids; Time Factors; Treatment Outcome | 2009 |
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Castration; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Pyrroles; Quality of Life; Sunitinib; Taxoids; Time Factors; Treatment Failure | 2010 |
Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endpoint Determination; Female; Half-Life; Humans; Indoles; Male; Middle Aged; Neoplasms; Pyrroles; Sunitinib; Taxoids | 2010 |
[Experience with sunitinib in hormone-resistant metastatic prostate cancer that is unresponsive to docetaxel].
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Compassionate Use Trials; Docetaxel; Drug Resistance, Neoplasm; Humans; Indoles; Male; Prospective Studies; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids; Treatment Failure | 2011 |
Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Indoles; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids | 2012 |
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Female; Humans; Indoles; International Agencies; Middle Aged; Prospective Studies; Pyrroles; Receptor, ErbB-2; Sunitinib; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Drug Administration Schedule; Drug Interactions; Feasibility Studies; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Receptor, ErbB-2; Sunitinib; Taxoids; Treatment Outcome | 2012 |
Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Platinum; Pyrroles; Salvage Therapy; Stomach Neoplasms; Sunitinib; Survival Rate; Taxoids; Tissue Distribution; Treatment Outcome; Young Adult | 2012 |
An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Humans; Indoles; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pyrroles; Receptor, ErbB-2; Sunitinib; Taxoids; Trastuzumab; Treatment Outcome | 2012 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Drug Discovery; Gossypol; Humans; Indoles; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Radiography; Retrospective Studies; Sunitinib; Survival Rate; Taxoids; Time Factors | 2014 |
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Humans; Indoles; Kaplan-Meier Estimate; Lymphopenia; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids; Treatment Outcome | 2014 |
Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Hemoglobins; Humans; Indoles; Inflammation; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Placebos; Prednisone; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Retrospective Studies; Sunitinib; Taxoids | 2014 |
Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Cell Hypoxia; Cell Proliferation; Docetaxel; Female; Gene Expression Profiling; Humans; Indoles; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Positron-Emission Tomography; Prospective Studies; Pyrroles; Sunitinib; Taxoids; Tomography, X-Ray Computed | 2015 |
Evaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxan) and Cisplatinum Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer: Stage 1 of a Simon 2 Stage Clinical Trial. [Corrected].
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pyrroles; Salvage Therapy; Sunitinib; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.
Topics: Adult; Aged; Disease-Free Survival; Docetaxel; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prednisone; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Pyrroles; Quality of Life; Salvage Therapy; Sunitinib; Taxoids | 2016 |
Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Management; Docetaxel; Follow-Up Studies; Humans; Indoles; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Sunitinib; Survival Rate; Taxoids | 2016 |
A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Docetaxel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms; Prognosis; Sunitinib; Survival Rate | 2020 |
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Spermine; Sunitinib | 2021 |
19 other study(ies) available for docetaxel anhydrous and su 11248
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Microtubules; Molecular Docking Simulation; Molecular Structure; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship | 2017 |
Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Proliferation; Cetuximab; Docetaxel; Gene Expression Profiling; Humans; Indoles; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sunitinib; Survival Rate; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indoles; Infusions, Intravenous; Male; Mice; Mice, Nude; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids; Xenograft Model Antitumor Assays | 2008 |
Sunitinib in breast cancer: friend or foe.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Indoles; Pyrroles; Sunitinib; Taxoids | 2009 |
Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Docetaxel; Female; Humans; Indoles; Liver Neoplasms; Lymph Node Excision; Mastectomy; Middle Aged; Pyrroles; Sunitinib; Taxoids; Tomography, X-Ray Computed | 2009 |
Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Indoles; Mice; Mice, Nude; Nasopharyngeal Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Taxoids; Xenograft Model Antitumor Assays | 2011 |
[Comment to: "Experience with sunitinib in hormone-resistant metastatic prostate cancer that is unresponsive to docetaxel"].
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Indoles; Male; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids; Treatment Failure | 2011 |
Concurrent and sequential administration of sunitinib malate and docetaxel in human non-small cell lung cancer cells and xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Cells, Cultured; Docetaxel; Human Umbilical Vein Endothelial Cells; Humans; Immunoblotting; Indoles; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Pyrroles; Sunitinib; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2012 |
Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Taxoids; Time Factors | 2011 |
The role of hypoxia-inducible factor-1α and -2α in androgen insensitive prostate cancer cells.
Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Insulin-Like Growth Factor I; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-met; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sorafenib; Sunitinib; Taxoids; Zinc Sulfate | 2013 |
Neuroendocrine tumor of the gallbladder.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Catheter Ablation; Cisplatin; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Female; Gallbladder; Gallbladder Neoplasms; Gemcitabine; Humans; Indoles; Middle Aged; Pyrroles; Sunitinib; Taxoids; Ultrasonography | 2013 |
American Society of Clinical Oncology Annual Meeting 2013.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Medical Oncology; Multicenter Studies as Topic; Oximes; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Societies, Medical; Sulfones; Sunitinib; Taxoids; Treatment Outcome; Triazoles; United States | 2013 |
The immunocytokine NHS-IL12 as a potential cancer therapeutic.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Docetaxel; Female; Humans; Immunoglobulin G; Immunomodulation; Indoles; Interferon-gamma; Interleukin-12; Lymphocyte Activation; Macaca fascicularis; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms, Experimental; Protein Engineering; Pyrroles; Recombinant Fusion Proteins; Sunitinib; Survival Rate; Taxoids; Tumor Burden | 2014 |
Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Caspases; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Indoles; Male; Phosphorylation; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Pyrroles; Quinolines; Sunitinib; Taxoids; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors.
Topics: Angiogenesis Inhibitors; Breast Neoplasms; Cohort Studies; Docetaxel; Female; Gene Expression; Genomics; Hemangioendothelioma; Hormones; Humans; Indoles; Microvessels; Middle Aged; Prognosis; Pyrroles; Sunitinib; Taxoids; Transcription, Genetic | 2016 |
Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
Topics: Aminoacetonitrile; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Humans; Indoles; Mice, Nude; Pyrroles; Sunitinib; Taxoids; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms | 2017 |
Primary Cardiac Leiomyosarcoma: A 27-Month Survival with Surgery and Chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Docetaxel; Doxorubicin; Fatal Outcome; Gemcitabine; Heart Neoplasms; Humans; Ifosfamide; Indoles; Leiomyosarcoma; Life Support Care; Male; Mesna; Pyrroles; Sunitinib; Taxoids | 2017 |
Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Calcitriol; Carcinoma, Non-Small-Cell Lung; Cholecalciferol; Cisplatin; Cytostatic Agents; Dihydroxycholecalciferols; Docetaxel; Female; Humans; Imatinib Mesylate; Indoles; Lung Neoplasms; Mice, SCID; Proto-Oncogene Proteins c-sis; Pyrroles; Sunitinib; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2018 |